Skip Navigation

COVID-19 Update

Find a Doctor

Find a Researcher

Researchers

Jonathan Allen Webster, M.D.

Photo of Dr. Jonathan Allen Webster, M.D.
  • Assistant Professor of Oncology

Specializes in: Adults (18+ years)

Male

Expertise

Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Internal Medicine, Oncology

Research Interests

Immunotherapy; Acute Leukemias

Request an Appointment

Insurance Information

Maryland

410-955-8964

Outside of Maryland

410-464-6641
Request Appointment

International Patients

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Fax: 410-614-7279

The Bunting Blaustein Cancer Research Building

1650 Orleans Street
Baltimore, MD 21287 map

Background

Dr. Webster is an Assistant Professor of Oncology at The Johns Hopkins University School of Medicine.  He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. 

Dr. Webster is board certified in internal medicine and medical oncology.

Dr. Webster has expertise in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS).

Dr. Webster received his medical degree from The Stanford University School of Medicine. He completed residency training in internal medicine at Johns Hopkins followed by a fellowship in medical oncology.  He completed the Science of Clinical Investigation curriculum at the Johns Hopkins Bloomberg School of Public health.

Dr. Webster is a member of the American Society of Hematology, and the American Society of Clinical Oncology.

Dr. Webster’s research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of acute leukemias (ALL and AML).  He has specific expertise in the use of maintenance therapies following bone marrow transplantation.  He has developed novel clinical trials utilizing immunotherapy for the treatment of ALL and the prevention of post-transplant relapse in both ALL and AML.  He serves as the Principal Investigator for these trials of post-transplant maintenance strategies, as well as the site PI for multi-center trials that are currently being conducted through the Eastern Co-operative Oncology Group (ECOG)-ACRIN and Experimental Therapeutics Clinical Trials Network (ETCTN).  As the leader of the adult ALL program at Johns Hopkins, he has focused on increasing clinical trial enrollments and improving outcomes in adult ALL.

...read more

Titles

  • Assistant Professor of Oncology

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD, Stanford University School of Medicine (2011)

Residencies

  • Johns Hopkins University School of Medicine / Internal Medicine (2014)

Fellowships

  • Johns Hopkins University School of Medicine / Medical Oncology (2017)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2014)
  • American Board of Internal Medicine / Medical Oncology (2016)

Research & Publications

Research Summary

Dr. Webster’s research is focused on improving outcomes for patients with ALL and AML.  His primary research interests include the incorporation of immunotherapy and post-transplant maintenance therapies to prevent disease relapse following allogeneic bone marrow transplantation.  He has overseen the development of a biobank of adult ALL samples at JHH and works in collaboration with Drs. Leo Luznik and Ivana Gojo to understand the interplay between the immune system and both conventional chemotherapy and immunotherapy.

Clinical Trial Keywords

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia

Selected Publications

View all on Pubmed

Smith BD, Webster JA. Rare Acute Leukemias . In: Textbook of Uncommon Cancers. Hoboken, NJ: Wiley-Blackwell; 2017. Chapter 50.

Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, Rosner GL, Gojo I, Kinders R, Wang L, Doyle LA, Huntoon CJ, Karnitz LM, Kaufmann SH, Karp JE, Smith BD. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leuk Res. 2017;61:108-116

Webster JA, Pratz KW. Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma. 2018 Feb; 59(2): 274

Webster J, Smith BD The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia. Clin Ther. 2019 Feb;41(2):336-349. doi: 10.1016/j.clinthera.2018.12.013. Epub 2019 Jan 30

Sterling C1, Webster J Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia. Am J Hematol. 2020 May;95(5):529-547. doi: 10.1002/ajh.25750. Epub 2020 Feb 19

Contact for Research Inquiries

Office
1650 Orleans Street
Baltimore, MD 21287 map

Activities & Honors

Honors

  • Robert E. Stowell Post-doctoral Fellow in Pathology, Stanford University, 2008 - 2009
  • Samuel Smith Leukemia Fellow, Johns Hopkins University, 2016 - 2017
  • Chief Fellow, Johns Hopkins University, 2016 - 2017
  • Conquer Cancer Foundation/Norman Rales Young Investigator Award, 2017

Memberships

  • American Society of Hematology, 2015
  • American Society of Clinical Oncology, 2014

Professional Activities

  • Journal Peer Reviewer, Frontiers Oncology, 2020
  • Journal Peer Reviewer, JAMA Oncology, 2020
  • Journal Peer Reviewer, British Journal of Hematology, 2020
  • Journal Peer Reviewer, Cancer Management and Research, 2018
  • Journal Peer Reviewer, OncoTargets and Therapy

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile
back to top button